NGM BIOPHARMACEUTICALS INC·4

Mar 6, 5:12 PM ET

Nolan Mangini Siobhan 4

4 · NGM BIOPHARMACEUTICALS INC · Filed Mar 6, 2023

Insider Transaction Report

Form 4
Period: 2023-03-02
Nolan Mangini Siobhan
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2023-03-02+76,00076,000 total
  • Award

    Stock Option (Right to Buy)

    2023-03-02+228,000228,000 total
    Exercise: $4.36Exp: 2033-03-01Common Stock (228,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-03-02+200,000200,000 total
    Exercise: $4.36Exp: 2033-03-01Common Stock (200,000 underlying)
Footnotes (3)
  • [F1]Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
  • [F2]The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
  • [F3]1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION